Expand MBRX Menu
MBRX MENU

MBRX Latest Press Releases

-- September 25, 2026 --

Annamycin Turns 'Cold' Pancreatic Tumors 'Hot' in New Preclinical Data Presented at AACR Globe Newswire 1:05 PM

-- September 23, 2026 --

Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040 Globe Newswire 8:25 AM

-- September 14, 2026 --

Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings Globe Newswire 8:35 AM

-- September 11, 2026 --

Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand Globe Newswire 8:30 AM

-- August 27, 2026 --

JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs ACCESS Newswire 9:01 AM
Moleculin CEO, Walter Klemp, Participates in the Virtual Investor 'Why Now' On-Demand Conference Globe Newswire 9:01 AM

-- August 14, 2026 --

Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial Globe Newswire 8:30 AM

-- July 31, 2026 --

Moleculin Announces Pricing of $9.3 Million Public Offering Globe Newswire 10:12 AM
Moleculin's MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients Globe Newswire 8:10 AM

-- July 6, 2026 --

Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment Globe Newswire 8:33 AM

-- June 30, 2026 --

Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control Globe Newswire 8:30 AM

-- June 5, 2026 --

Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML Globe Newswire 8:29 AM

-- June 4, 2026 --

Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor "What This Means" Segment Globe Newswire 8:31 AM

-- May 29, 2026 --

Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits Globe Newswire 8:21 AM

-- May 21, 2026 --

Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin Globe Newswire 5:02 PM

-- May 15, 2026 --

Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial Globe Newswire 8:30 AM

-- May 13, 2026 --

Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks Globe Newswire 8:00 AM

-- May 12, 2026 --

Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits Globe Newswire 9:30 AM

-- May 8, 2026 --

Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin Globe Newswire 8:45 AM
Market Data Delayed 15 Minutes